Pennsylvania-based pharmaceutical company Certara has entered a definitive agreement to acquire cheminformatics software provider Chemaxon for an undisclosed sum.
Post-acquisition, Certara plans to combine its technology with Chemaxon's to enhance prediction and analytical capabilities in drug discovery. The company aims to offer a comprehensive data and predictive analytics platform to improve decision-making from discovery through commercialization in the life sciences sector.
Certara specializes in providing software products and technology-enabled services, including AI-powered solutions to the pharmaceutical sector. The company's focus is on model-informed drug development, offering solutions that predict pharmacokinetics and pharmacodynamics through software services such as Simcyp Simulator, which predicts drug behavior within the human body, and Phoenix WinNonlin IVIV for in vitro-in vivo correlation (IVIVC) studies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.